Yes, Birth Control Can Help with Acne
Combined oral contraceptives (COCs) are conditionally recommended for acne treatment in women of reproductive age, with moderate certainty evidence showing they reduce both inflammatory and non-inflammatory lesions compared to placebo. 1
Evidence for Effectiveness
The 2024 American Academy of Dermatology guidelines establish that COCs work through anti-androgenic mechanisms by:
- Decreasing ovarian androgen production
- Increasing sex hormone-binding globulin
- Reducing free testosterone that activates androgen receptors
- Blocking 5α-reductase activity 1
Clinical trial data demonstrates that at 6 months, COCs achieve:
- 45% greater likelihood of clear or almost clear skin (RR 1.45)
- 15.81% greater reduction in inflammatory lesions
- Significant reductions in both comedones and papules 1
A Cochrane review of 31 trials with 12,579 participants confirmed all six COCs evaluated in placebo-controlled trials effectively reduce both inflammatory and non-inflammatory facial acne lesions 2.
FDA-Approved Options
Four COCs are FDA-approved specifically for acne treatment in women who desire oral contraception:
- Norgestimate/ethinyl estradiol
- Norethindrone acetate/ethinyl estradiol/ferrous fumarate
- Drospirenone/ethinyl estradiol
- Drospirenone/ethinyl estradiol/levomefolate 1
All are available in generic forms, which improves accessibility.
Choosing the Right Formulation
The differences between various COC formulations for acne are less clear, but some patterns emerge:
- Fourth-generation progestins (drospirenone, dienogest) have inherent anti-androgenic properties and may offer slight advantages 1
- Third-generation progestins (norgestimate, desogestrel) are less androgenic than earlier generations 1
- First and second-generation progestins (norethindrone, levonorgestrel) have more androgenic potential when used alone but still provide net anti-androgenic effects when combined with estrogen 1
For women primarily seeking acne treatment with contraception, norgestimate-containing COCs offer an optimal balance of efficacy and lower thrombotic risk 3.
Critical Safety Considerations
Venous thromboembolism (VTE) risk must be discussed:
- Non-COC users: 1-5 per 10,000 person-years
- COC users: 3-9 per 10,000 person-years
- Drospirenone-containing COCs: 10 per 10,000 person-years
- For comparison, pregnancy: 5-20 per 10,000 person-years 1
Avoid COCs in women who:
- Are over 35 years and smoke tobacco
- Have hypertension, diabetes, or migraines
- Have history of thromboembolism 1
Important Pitfalls to Avoid
Progestin-only contraceptives (pills, injections, IUDs, implants) may worsen acne due to their androgenic effects without the counterbalancing estrogen component 1. This is a common mistake—ensure you prescribe combined oral contraceptives, not progestin-only formulations.
Timeline and Patient Counseling
Acne improvement typically requires 6 months of consistent use to see maximal benefit 1. Set realistic expectations with patients that this is not a rapid treatment.
COCs should not be used as monotherapy for acne—they work best as part of a comprehensive acne treatment plan that may include topical retinoids, benzoyl peroxide, or other appropriate therapies based on acne severity 3.
When COCs Are Particularly Appropriate
COCs are especially valuable for women who:
- Desire contraception and have acne
- Have signs of hyperandrogenism (hirsutism, irregular menses)
- Have failed or cannot tolerate other acne treatments
- Have contraindications to isotretinoin
- Experience premenstrual acne flares 1
The conditional (rather than strong) recommendation reflects variability in patient values regarding contraception and the need for shared decision-making, not uncertainty about efficacy 1.